Be Biopharma vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
$274M total raised including $92M Series C with Bristol Myers Squibb. Phase 1/2 active for BE-101 in Hemophilia B. CRISPR-engineered B cells as continuous protein factories.
About
Be Biopharma uses CRISPR to engineer a patient's own B cells into continuous protein-secreting factories — a one-time treatment designed to replace lifelong enzyme replacement therapy for rare metabolic diseases. The company has raised $274 million in total financing including a $92 million Series C co-led by Nextech Invest and Bristol Myers Squibb, with ARCH Venture Partners as a continuing investor, and has an active Phase 1/2 trial (BeCoMe-9) for BE-101 in Hemophilia B.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.